Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Inhibikase Therapeutics Q4 EPS $(0.64) Beats $(0.85) Estimate, Sales $1.00K Down From $63.57K YoY

Author: Happy Mohamed | March 27, 2024 11:45pm
Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(0.85) by 24.71 percent. This is a 37.25 percent increase over losses of $(1.02) per share from the same period last year. The company reported $1.00 thousand in sales this quarter. This is a 98.43 percent decrease over sales of $63.57 thousand the same period last year.

Posted In: IKT


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist